Condrocitele cartilajului articular prin solicitare se
deformeaza, pentru ca dupa solicitare sa revina la forma initiala, conferindu-i proprietati elastice
40 Glucozaminoglicani
sulfatati cu sinergie promoveaza sinteza de lichid sinovial
41 Glucozamina
sulfat, Condroitina si Mangan cu eficienta in menagementulde osteoartrita
42 Glucozamina sulfat, Condroitina si Mangan indicat la imbolnavirile
degenerative ale
articulatiilor, studiu randomizat, dublu-orb, placebo controlat
43 Glucozamina
sulfat in vindecarea ranilor
44 Glucozamina
sub forma de gel in vindecarea ranilor fara sa lase cicatrice, previne formare
de tesut cu cicatrice, foarte important la ingrijirea pielii
45 Suplimente
nutritionale pe cale orala continind Glucozamina, aminoacizi, Vitamine Minerale
si Antioxidanti la ingrijirea pielii cu reducerea ridurilor cu 34%, studiu
preliminar
46 Glucozamina
un produs natural pentru ingrijirea pielii, reda tonusul si elasticitatea pierduta
47Metilsulfonilmetan (MSM) in cosmetica
Produse naturale ca Glucozamina, Metilsulfonilmetan (MSM) pentru
ingrijirea pielii
48 Glucozamina
reduce aparenta faciala de hiperpigmentatie
49 Imbatranirea
pielii si tratament: Anti-Aging Skin Care
50 Crestere nivelului seric de glucozaminoglicani prin administrarea orala de
Condroitina
Glucozamina creste nivelul in tesuturi
51 Receptori in derma si agentii Anti-Aging
52 Nivelul
de Glucozamina la persoane cu cardiopatia ischemica cu sau fara diabet tip
II
53 Glucozamina
la cardiopatia ischemica
54 Mucopolizaharid - Glucozaminoglicani in tratamentul de ateroscleroza
55 Glucozamina
cu efect distinct de protectie in ateroscleroza
56 Condroitina indicat in bolile coronariene, reducerea leziunilor vasculare
in arterile
coronariene si aorta
Glucozamina reduce leziunea aterosclerotica
57 Glucozamina
cu efect retard in aterogeneza prin promovarea de Heparan Sulfat Proteoglicani
58 Relatia intre Sulfat Glucozaminoglicani si continutul de colesterol in aorta
aterosclerotica
umana
Glucosamina reduce colesterolul
59 Lipoproteina
moduleaza subendoteliala Heparan Sulfat Proteoglicani (HSPG) si procesul aterogenic
Glucosamina cu efect la macrofage
60 Expresia
umana de Perlecan este un recombinat Heparan Sulfat Proteoglican (HSPG) cu
20 kDa Glucozaminoglicani
61 Glucozamina
cu actiune de inhibare activari plachetare
62 Heparan
Sulfat Proteoglican la modelul eperimental de diabet, Perlecan un membru al
Heparan Sulfat Proteoglican la complicatiile de diabet
63 Glucozamina
cu efect de control al glucozei
64 Glucozamina
doza standard pentru 6 saptamini nu afecteaza rezistenta la insulina sau disfunctia
endoteliala la persoane obeze
65 Metilsulfonilmetan (MSM) statusul actual in medicina
66Metilsulfonilmetan (MSM) indicat la artrita,
studiu randomizat, dublu-orb, placebo controlat
67 Metilsulfonilmetan (MSM) indicat la artrita
cronica si reumatism
68Metilsulfonilmetan (MSM)
in uz farmaceutic si dietetic
Bibliografie-Referinte: Artrita Formula
Informatii din bibliografia electronica la tema: Nutritie si sanatate
1 Reginster
JY, Gillot V, Bruyere O, Henrotin Y. Evidence of nutriceutical effectiveness
in the treatment of osteoarthritis. Bone and Cartilage Metabolism Research
Unit, CHU Centre-Ville, Policliniques L. Brull, Quai Godefroid Kurth 45 (9
ème étage),
4020 LIEGE, Liège, Belgium. Curr Rheumatol Rep. 2000 Dec;2(6):472-7.
2 Deal
CL, Moskowitz RW.Nutraceuticals as therapeutic agents in osteoarthritis. The
role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Division
of Rheumatology, Case Western Reserve University School of Medicine, University
Hospitals, Cleveland, Ohio, USA. Rheum Dis Clin North Am. 1999 May;25(2):379-95. - Leffler CT, Philippi AF, Leffler SG,
et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint
disease of the knee or low back: a randomized double-blind, placebo-controlled
pilot study. Mil Med. 1999; 64:85-91.
3 Richy
F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and
symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a
comprehensive meta-analysis. Faculty of Medicine, Department of Public Health,
Public Health and Epidemiology, University of Liège, Liège, Belgium. Arch Intern
Med. 2003 Jul 14;163(13):1514-22.
4 Towheed
TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy
for treating osteoarthritis. Medicine, Community Health and Epidemiology, Queen's
University, Room 2066 Etherington Hall, Queen's University, Kingston, Ontario,
Canada, K7L 3N6. Cochrane Database Syst Rev. 2001;(1):CD002946.
- Zerkak D, Dougados M. The use of glucosamine therapy in osteoarthritis. Rheumatology
B Department, René Descartes University, AP-HP Cochin Hospital, 27 rue du Faubourg
Saint Jacques, Paris 75014, France. Curr Pain Headache Rep. 2004 Dec;8(6):507-11.
5 Setnikar
I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Rotta
Research Laboratorium S.p.A., Monza, Italy. Arzneimittelforschung.
1993 Oct;43(10):1109-13.
- Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine
oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline
glucosamine sulfate in man. Clinical Pharmacology Department, Rotta Research
Laboratorium/Rottapharm, Monza, Italy. Osteoarthritis Cartilage. 2005 Dec;13(12):1041-9.
Epub 2005 Sep
13.
6 Conte
A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects
of oral treatment with chondroitin sulfate.
Department
of Biologia Animale, University of Modena, Italy. Arzneimittelforschung. 1995
Aug;45(8):918-25.
7 Noack
W, Fischer M, Förster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis
of the knee. Department of Orthopedics-Evangelisches Waldkrankenhaus, Berlin,
Germany. Osteoarthritis Cartilage. 1994 Mar;2(1):51-9.
8 Herrero-Beaumont
G, Rovati LC, Castañeda S, Alvarez-Soria MA, Largo R. The reverse glucosamine
sulfate pathway: application in knee osteoarthritis. Rheumatology Department,
Joint and Bone Research Laboratory, Fundación Jiménez Díaz--Capio, Autonomous
University of Madrid, Avenida Reyes Católicos 2, 28040 Madrid, Spain. Expert
Opin Pharmacother. 2007 Feb;8(2):215-25.
9 Uitterlinden
EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J, Verhaar
JA, Weinans H, van Osch GJ. Glucosamine decreases expression of anabolic and
catabolic genes in human osteoarthritic cartilage explants.Erasmus MC, University
Medical Center Rotterdam, Department of Orthopaedics, The Netherlands. Osteoarthritis
Cartilage. 2006 Mar;14(3):250-7. Epub 2005 Nov 18.
10 Varghese
S, Theprungsirikul P, Sahani S, Hwang N, Yarema KJ, Elisseeff JH. Glucosamine
modulates chondrocyte proliferation, matrix synthesis, and gene expression.
Department of Biomedical Engineering, Johns Hopkins University School of Medicine,
Baltimore,
MD 21218, USA. Osteoarthritis Cartilage. 2007 Jan;15(1):59-68. Epub 2006 Jul
18.
11 Lippiello
L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic
synergy of glucosamine and chondroitin sulfate. Division of Orthopaedic Surgery,
Maricopa Medical Center, Phoenix, AZ, USA. Clin Orthop Relat Res. 2000
Dec;(381):229-40.
12 Drovanti
A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate
in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther.
1980;3(4):260-72.
13 Pujalte
JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine
sulphate in the basic treatment of osteoarthrosis. Curr Med
Res Opin. 1980;7(2):110-14.
14 Reginster
JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin
Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis
progression: a randomised, placebo-controlled clinical trial. Bone and Cartilage
Metabolism Research Unit (WHO Collaborating Center for Public Aspects of Osteoarticular
Disorders), University of Liege, Belgium. Lancet. 2001
Jan 27;357(9252):251-6.
15 Pavelká
K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine
sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized,
placebo-controlled, double-blind study. Department of Medicine and Rheumatology,
Charles University, Prague, Czech Republic. Arch Intern Med. 2002
Oct 14;162(18):2113-23.
16 Karel
Pavelká, MD, PhD; Jindriska Gatterová,
MD; Marta Olejarová, MD; Stanislav Machacek, MD; Giampaolo Giacovelli, PhD; Lucio C. Rovati, MD.
Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis A
3-Year, Randomized, Placebo-Controlled, Double-blind Study. Arch Intern Med.
2002;162:2113-2123
17 Bruyere
O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G,
Reginster JY. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal
women with knee osteoarthritis: evidence from two 3-year studies. WHO Collaborating
Center for Public Health Aspect of Osteoarticular Disorders, Liege, Belgium.
Menopause. 2004 Mar-Apr;11(2):138-43.
18 Poolsup
N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment
and the progression of knee osteoarthritis: systematic review of randomized
controlled trials. Department of Pharmacy, Faculty of Pharmacy, Silpakorn University,
Nakhon-Pathom,
Thailand. Ann Pharmacother. 2005 Jun;39(6):1080-7. Epub 2005 Apr
26.
19 Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy
and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3
x 400 mg/day vs placebo. Department of Rheumatology, Pitié Salpêtrière Hospital,
Paris, France. Osteoarthritis Cartilage. 1998 May;6 Suppl A:25-30.
20 Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral
chondroitin sulfate on the progression of knee osteoarthritis: a pilot study.
Department
of
Neuclid, University Hospital of Geneva, Switzerland. Osteoarthritis Cartilage.
1998 May;6 Suppl A:39-46.
21 Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of
chondroitin sulfate. Department of Human and Environmental Sciences, University
of Pisa,
Italy. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21.
22 Thie
NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen
for the treatment of temporomandibular joint osteoarthritis: a randomized double
blind controlled 3 month clinical trial. Orofacial Pain Clinic, Department
of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton,
Alberta, Canada. J Rheumatol. 2001 Jun;28(6):1347-55.
23 Müller-Fassbender
H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to
ibuprofen in osteoarthritis of the knee. Rheumazentrum, Bad Abbach, Germany.
Osteoarthritis
Cartilage. 1994 Mar;2(1):61-9.
24 Ruane
R, Griffiths P. Glucosamine therapy compared to ibuprofen for joint pain. Primary
Care and Community Pharmacy, King's College London. Br J Community Nurs. 2002
Mar;7(3):148-52.
25 Braham
R, Dawson B, Goodman C. The effect of glucosamine supplementation on people
experiencing regular knee pain. Department of Human Movement and Exercise Science,
University
of Western Australia, Crawley, Western Australia 6009. Rebecca. Br J Sports
Med. 2003 Feb;37(1):45-9; discussion 49.
26 Rejeski
WJ, Ettinger WH Jr, Shumaker S, Heuser MD, James P, Monu J, Burns R. The evaluation
of pain in patients with knee osteoarthritis: the knee pain scale. Department
of Health and Sport Science, Bowman Gray School of Medicine, Wake Forest University,
Winston-Salem, North Carolina, USA. J Rheumatol. 1995
Jun;22(6):1124-9.
27 Matheson
AJ, Perry CM. Glucosamine: a review of its use in the management of osteoarthritis.
Adis International Limited, Auckland, New Zealand. Drugs Aging.
2003;20(14):1041-60.
28 Russell
AL. Glucosamine in osteoarthritis and gastrointestinal disorders: an exemplar
of the need for a paradigm shift. Brampton Pain Clinic, Bramalea, Ontario,
Canada. Med Hypotheses. 1998 Oct;51(4):347-9.
29 McAlindon
T. Glucosamine and chondroitin for rheumatoid arthritis Bulletin on the Rheumatic
Diseases. 2001;50(7):1-4.
30 Constantz
RB. Hyaluronan, glucosamine and chondroitin sulfate: roles for therapy in
arthritis In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology.
Philadelphia: WB Saunders, 1998.
31 Crolle
G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled
clinical investigation. Curr Med
Res Opin. 1980;7(2):104-9.
32 D'Ambrosio
E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled
clinical investigation in arthrosis. Pharmatherapeutica. 1981;2(8):504-8.
33 Giordano
N, Nardi P, Senesi M, Palumbo F, Battisti E, Gonnelli S, Franci B, Campagna
MS, Gennari C. The efficacy and safety of glucosamine sulfate in the treatment
of
gonarthritis Istituto di Patologia Speciale Medica, Università degli Studi
di Siena. Clin Ter. 1996 Mar;147(3):99-105.
34 Mazieres
B, Loyau G, Menkes CJ, et al. Chondroitin sulfate in the treatment of gonarthrosis
and coxarthrosis. 5-months result of a multicenter double-blind controlled
prospective study using placebo [in French; English abstract]. Rev
Rhum Mal Osteoartic. 1992;59:466–472.
- L'Hirondel JL. Double-blind clinical study with oral administration of chondroitin
sulphate versus placebo in tibiofemoral gonarthrosis (125 patients) [in German].
Litera Rheumatol. 1992;14:77-84.
35 W-D
Mund-Hoyn. Konservative behandlung von
Wirbelsäulenarthrosen mit glucosaminsulphat un phenylbutazone. Therapiewoche 1980 30:
5922-8.
- Förster KK, Schmid K, Rovati LC. Efficacy of glucosamine
sulfate in osteoarthritis of the lumbar spine: a placebo-controlled, randomized,
double-blind
study. Arthritis Rheum 2000; 43 (Suppl.): 1613.
36 Bartolucci C, Cellai L, Corradini C, Corradini D, Lamba D, Veloná I. Chondroprotective
action of chondroitin sulfate. Competitive action of chondroitin sulfate on the
digestion of hyaluronan by bovine testicular hyaluronidase.Institute of Structural
Chemistry, Giordano Giacomello, CNR, Rome, Italy. Int J Tissue React. 1991;13(6):311-7.
- Pipitone VR. Chondroprotection with chondroitin sulfate. Department of Rheumatology,
University of Bari, Italy. Drugs Exp Clin Res. 1991;17(1):3-7.
37 Jeffrey JE, Gregory DW, Aspden RM. Matrix damage and chondrocyte viability
following a single impact load on articular cartilage. Department of Orthopaedics,
University of Aberdeen, Foresterhill, Scotland, United Kingdom. Arch Biochem
Biophys. 1995 Sep 10;322(1):87-96.
38 Borrelli J Jr, Torzilli PA, Grigiene R, Helfet DL. Effect of impact load
on articular cartilage: development of an intra-articular fracture model. Department
of Orthopaedic Surgery, School of Medicine, Washington University, Barnes-Jewish
Hospital, St. Louis, Missouri, USA. J Orthop Trauma. 1997 Jul;11(5):319-26.
39 McCarty
MF. Enhanced synovial production of hyaluronic acid may explain rapid clinical
response to high-dose glucosamine in osteoarthritis. Nutrition 21, San Diego,
CA 92109, USA.Med Hypotheses. 1998 Jun;50(6):507-10.
40 McCarty
MF, Russell AL, Seed MP. Sulfated glycosaminoglycans and glucosamine may synergize
in promoting synovial hyaluronic acid synthesis. NutriGuard Research, La Jolla,
CA, USA. Med Hypotheses. 2000 May;54(5):798-802.
41 Das
A, Jr., Hammad TA. Efficacy of a combination of FCHG49 glucosamine hydrochloride,
TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate
in the management of knee osteoarthritis. Osteoarthritis Cartilage. 2000;8(5):343-350.
42 Leffler CT, Phillipi AF, Leffler SG, et al. Glucosamine, chondroitin, and
manganese ascorbate for degenerative joint disease of the knee or low back:
a randomized,
double-blind, placebo-controlled
pilot study. Mil Med. 1999;
164:85-91.
43 McCarty
MF. Glucosamine for wound healing. Nutrition 21, San Diego, CA 92109, USA.
Med Hypotheses. 1996 Oct;47(4):273-5.
44 Shaunak
S, Thomas S, Gianasi E, et al. Polyvalent dendrimer glucosamine conjugates
prevent scar tissue formation. Nature Biotechnology. 2004;22(8):977-984.
45 Murad
H, Tabibian MP. The effect of an oral supplement containing glucosamine, amino
acids, minerals, and antioxidants on cutaneous aging: a preliminary study.
Journal of Dermatology Treatment. 2001;12(1):47-51.
46 Bissett
DL. Glucosamine: an ingredient with skin and other benefits. J Cosmet Dermatol.
2006 Dec;5(4):309-15.
47 Herschler,
R. J., "Methylsulfonylmethane
in Cosmetics", 1984, Cardinal Associates, Inc.
48 Bissett
DL, Robinson LR, Raleigh PS, et al. Reduction in the appearance of facial hyperpigmentation
by topical N-acetyl glucosamine. J Cosmet Dermatol. 2007 Mar;6(1):20-6.
49 Baumann
L. Skin ageing and its treatment. Department of Dermatology, University of
Miami, Miami Beach, FL, USA. J Pathol. 2007 Jan;211(2):241-51.
50 Baici
A, Horler D, Moser B, et al. Analysis of glycosaminoglycans in human serum
after
oral administration of chondroitin
sulfate. Rheum Int.
1992; 12:81-88.
51 Ghersetich
I, Troiano M, De Giorgi V, Lotti T. Receptors in skin ageing and antiageing
agents. Department of Dermatology, University of Florence, Via Lorenzo il
Magnifico 104,
50129 Florence, Italy. Dermatol Clin. 2007 Oct;25(4):655-62.
52 Nowak
A, Szczesniak L, Rychlewski T, Dylewicz P, Przywarska I. Glucosamine levels
in people with ischaemic [sic] heart disease with and without type II diabetes.
Pol Arch Med Wewn. 1998;100(5):419-425.
53 Olszewski
AJ, Szostak WB, McCully KS. Plasma glucosamine and galactosamine in ischemic
heart disease. National Institute of Food and Nutrition, Warsaw, Poland. Atherosclerosis.
1990 May;82(1-2):75-83.
54 Morrison
LM, Quilligan JJ Jr, Murata K, Schjeide OA, Freeman L, Ershoff BH. Treatment
of atherosclerosis with acid mucopolysaccharides. Exp Med Surg. 1967;25(1):61-71.
55 Duan W, Paka L, Pillarisetti S. Distinct effects of glucose and glucosamine
on vascular
endothelial and smooth muscle cells: evidence for a protective role for glucosamine
in atherosclerosis. Cardiovascular Diabetology. 2005;4:16.
56 Morrison
LM, Enrick L. Coronary heart disease: reduction of death rate by chondroitin
sulfate A. Angiology. 1973; 24:269-287.
- Morrison LM, Bajwa GS, Alfin-Slater RB, Ershoff BH. Prevention of vascular
lesions by chondroitin sulfate A in the coronary artery and aorta of rats induced
by a hypervitaminosis D, cholesterol-containing diet. Atherosclerosis. 1972;
16:105-118
57 McCarty
MF. Glucosamine may retard atherogenesis by promoting endothelial production
of heparan sulfate proteoglycans. Nutrition 21, San Diego, CA 92109, USA. Med
Hypotheses. 1997 Mar;48(3):245-51.
58 Hollmann
J, Schmidt A, von Bassewitz DB, Buddecke E. Relationship of sulfated glycosaminoglycans
and cholesterol content in normal and atherosclerotic human aorta. Arteiosclerosis.
1989;9:154–158.
59 Pillarisetti
S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans
(perlecan) and atherogenicity. Laboratory of Translational Research, North
Shore, Long
Island Jewish Health System, Manhasset, NY, USA. Trends Cardiovasc Med. 2000
Feb;10(2):60-5.
60 Graham
LD, Whitelock JM, Underwood PA. Expression of human perlecan domain I as
a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains.
CSIRO Molecular
Science, Sydney Laboratory, North Ryde, New South Wales, 1670, Australia.
lloyd.
Biochem Biophys Res Commun. 1999 Mar 24;256(3):542-8.
61 Lu-Suguro
JF, Hua J, Sakamoto K, Nagaoka I. Inhibitory action of glucosamine on platelet
activation in guinea pigs. Inflammation Research. 2005;54(12):493-499.
62 Conde-Knape
K (2001). Heparan sulfate proteoglycans in experimental models of diabetes:
a role for perlecan in diabetes complications. Diabetes Metab. Res. Rev.
17 (6):
412–21. doi:10.1002/dmrr.236. PMID 11757076.
63 Stumpf
JL, Lin SW. Effect of glucosamine on glucose control. University of Michigan
Health System and College of Pharmacy, Ann Arbor, MI 48109, USA. Ann Pharmacother.
2006 Apr;40(4):694-8. Epub 2006 Mar 28.
64 Muniyappa
R, Karne RJ, Hall G, Crandon SK, Bronstein JA, Ver MR, Hortin GL, Quon MJ.
Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin
resistance
or endothelial dysfunction in lean or obese subjects. Chief, Diabetes Unit,
National Center for Complementary and Alternative Medicine, National Institutes
of Health,
10 Center Dr., Bldg. 10, Rm. 6C-205, Bethesda, MD 20892, USA. Diabetes. 2006
Nov;55(11):3142-50.
65 Jacob,
S. W., "The Current Status of MSM
in Medicine," Am. Acad.
Meri. Prev., 1983.
66 M.
Lawrence, M.D., Ph.D. Assistant Clinical Professor, U.C.L.A. LIGNISUL MSM (Methylsulfonylmethane)
A DOUBLE BLIND STUDY OF ITS USE IN DEGENERATIVE ARTHRITIS(A
Preliminary Correspondence)
School of Medicine Los Angeles, California 4/10/01. - M. Lawrence, M.D., Ph.D, Sanchez, D.C.,
C.C.S.P., Grossman, D.C. LIGNISUL MSM (Methylsulfonylmethane) IN THE TREATMENT
OF ACUTE ATHLETIC
INJURIES 3/12/01.
67 Senturia BD. Results of treatment of chronic arthritis and rheumatoid conditions
with colloidal sulphur. J Bone Joint Surg 1934;16:119-25.
1934.
68 Herschler,
R. J., "Dietary and Pharmaceutical
uses of Methysulfonylmethane Compositions Comprising It," United
States Patent 4,512,421:
Literatura
Mindell EL. The MSM Miracle, Enhance your health with organic sulfur.
Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate.
Evidenta efectiva cu suplimente nutritive ca Artrita Formula Glucosamina sulfat, Condroitin sulfat si Metilsulfonilmetan (MSM) in osteoartrita.
Artrita
Formula cu Glucozamina din extract de chitina
